Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + fruquintinib for third-line RAS/BRAF wild-type colorectal cancer
ChiCTR2000038227Phase 2Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and cetuximab in colorectal cancer (CRC), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Safety, Grade 3/4 incidence of adverse events and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
fruquintinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000038227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038227.